{"id":"W4389242999","doi":"10.1182/blood-2023-182536","title":"Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba; BC Cancer Agency; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Cohort; Refractory (planetary science); Lymphoma; Diffuse large B-cell lymphoma; Gastroenterology; Neutropenia; Febrile neutropenia; Oncology; Phases of clinical research; Cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002484122,0.001279693,0.001883573,0.0004669905,0.0006435267,0.001292255,0.0008379271,0.0009675597,0.001710617],"category_scores_gemma":[0.001321068,0.0006078691,0.002443901,0.0004761542,0.0007231764,0.0009452488,0.0005114616,0.002030213,0.0004640465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001550948,"about_ca_system_score_gemma":0.002180365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001768577,"about_ca_topic_score_gemma":0.003919818,"domain_scores_codex":[0.9991585,0.0003860824,0.00005412968,0.0001620072,0.00009458117,0.0001447732],"domain_scores_gemma":[0.9987264,0.0001778652,0.0003200401,0.0001728381,0.0001015986,0.0005012375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7442899,0.03909518,0.1206328,0.0005772557,0.00805381,0.000519207,0.0006892469,0.001613603,0.0234372,0.0001514344,0.003469749,0.05747059],"study_design_scores_gemma":[0.4142807,0.3609603,0.2049766,0.0001246559,0.005982807,0.001099057,0.0003761031,0.002089554,0.004039077,0.0003949782,0.005551363,0.0001248698],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971727,0.0008124223,0.0001506532,0.0001109947,0.00003224416,0.0006338771,0.0007753452,0.00001866177,0.0002930725],"genre_scores_gemma":[0.9954065,0.0005865999,0.0005078056,0.0003654219,0.0001244493,0.0007230263,0.001937743,0.00001222142,0.0003363371],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002484122,"threshold_uncertainty_score":0.01313746,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02301311069555842,"score_gpt":0.3045561159586645,"score_spread":0.281543005263106,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}